Quick Answer
SAB Biotherapeutics, Inc. reported Stockholders Equity of $151.49 million for fiscal year 2025.
SAB Biotherapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $151.49M | +483.4% |
| 2024 | $25.97M | -54.7% |
| 2023 | $57.30M | +84.5% |
| 2022 | $31.06M | -16.3% |
| 2022 | $37.12M | -10.0% |
| 2022 | $41.26M | +7.0% |
| 2021 | $38.55M | -1.2% |
| 2020 | $39.01M | +407.0% |
| 2019 | $7.69M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $165.07M | +347.3% | +1273.8% |
| June 30, 2025 | $12.02M | -73.9% | -43.9% |
| March 31, 2025 | $21.41M | -59.5% | -17.6% |
| December 31, 2024 | $25.97M | -54.7% | -29.6% |
| September 30, 2024 | $36.90M | +141.9% | -20.0% |
| June 30, 2024 | $46.12M | +133.9% | -12.7% |
| March 31, 2024 | $52.82M | +116.5% | -7.8% |
| December 31, 2023 | $57.30M | +84.5% | +275.6% |
- SAB Biotherapeutics, Inc. showed an increase of +483.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, SAB Biotherapeutics, Inc.’s stockholders equity has grown by 1868.9% (from $7.69 million to $151.49 million).
- The most recent figure is from SAB Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: